Drug restrictions cut costs without negative impact on patients: study

A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. » Read More

Managing high cost of speciality drugs key challenge for employers, payers

Managing and monitoring the increasingly high cost of speciality drugs will be a key challenge to control insurance prices over the next two years, say employers and third party payers. » Read More

Medicare Part D premiums to see only slight rise in 2017

WASHINGTON, D.C. -- Medicare Part D premiums will see only a modest rise in 2017, despite costs to taxpayers growing faster than parts A and B, the Centers for Medicare and Medicaid Services (CMS) recently said in a statement. » Read More

Medicare premium to stay stable

With only the slightest of increases, Medicare recently announced that the average monthly cost for a Medicare Part D prescription drug plan in 2017 is projected to remain reasonably stable at approximately $34. » Read More

Cancer drug delivery fast shifting, more changes likely

Jostling among hospitals, pharmacies, doctors, and third-party payers over the delivery of specialty cancer drugs is likely to intensify, according to experts observing the already fast shifting field of oncology treatment channeling. » Read More

Congress passes prescription-drug bill targeting opioid abuse

This week, Congress passed the Comprehensive Addiction and Recovery Act (CARA), which aims to combat prescription drug abuse, especially opioids. » Read More

Economist: Disclosing wholesale drug prices would be costly for consumers

Forcing drug companies to disclose wholesale prices would likely put more pressure on consumers’ wallets, health economist Devon Herrick said. » Read More

Indiana pharmacist charged with allegedly filling fraudulent prescriptions

Indiana pharmacist Kevin Foster was recently arrested and charged with Filling an Invalid Prescription for Legend Drugs by a Pharmacist, Marion County Prosecuting Attorney Terry Curry announced. » Read More

Fee request for 340B program eliminates purpose of program, critics say

In keeping with President Obama's budget request, a Senate committee recently approved a request to create a small fee for the 340B drug discount program. » Read More

Pfizer acquires Anacor

Pfizer Inc. recently announced its completed acquisition of Anacor Pharmaceuticals, Inc., giving each outstanding Anacor common stock share the opportunity to gain $99.25 net in cash as part of the acquisition. » Read More

+ More News

Latest News

Raptor to present at ERS International Congress 2016

Raptor Pharmaceuticals Corp., a biopharmaceutical company focused on the development and commercialization of transformative treatments to treat rare diseases, has announced its participation in the European Respiratory Society (ERS) International Congress 2016. » Read More

Health Center Partners to receive $1.5 million from HHS

Health Center Partners, a group of community health centers in San Diego, Riverside and Imperial counties in California, recently announced that is has been named the recipient of $1.5 million from the U.S. Department of Health and Human Services (HHS). » Read More

Stanley Crooke recipient of E. B. Hershberg Award

Stanley Crooke, founder, CEO and chairman of Ionis Pharmaceuticals, has been named the recipient of the E. B. Hershberg Award by the American Chemical Society for significant discoveries in medicinally active substances. » Read More

Fexapotide placebo crossover study reveals lower incidence of surgery

Men who received placebo and subsequent treatment with fexapotide show lower surgery rates. » Read More

CVS Health Research Institute releases new study showing interventions based on patient populations can save costs

The CVS Health Research Institute this week released the findings of a new study showing that it is extremely cost-efficient to intervene in order to increase medication adherence in patients suffering from common chronic conditions. » Read More

FDA tentatively approves generic version of Suprep

Perrigo also confirms lawsuit over generic version of Mirvaso topical gel. » Read More

First patient in CytoDyn PRO 140 study reaches two years of complete virologic suppression

CytoDyn Inc., a company specializing in biotechnology that is dedicated to the development of new antibody therapies for the treatment of human immunodeficiency virus (HIV), recently announced that the first of 11 patients with HIV-1 in its Phase 2b extension study of PRO 140 has achieved two years of complete virologic suppression. » Read More

BioPharmX Phase IIa trial shows 90 percent reduction in acne

BPX-01 topical minocycline reduces P. acnes after four weeks without entering bloodstream. » Read More

Missouri ‘expert witness’ debate watched closely by health products, pharma industries

In the wake of a large jury verdict against Johnson & Johnson, the health products industry is closely watching a debate over expert witness standard legislation in Missouri. » Read More

+ More News